Scripps Clinic

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Ovarian cancer2 trials
• Aortic stenosis1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Melanoma1 trial
• Neuroendocrine tumours1 trial
• Pancreatic cancer1 trial
• and 3 more

Phase

• Phase 22 trials
• Phase 31 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Boston Scientific Corporation1 trial
• Bristol-Myers Squibb1 trial
• Corvia Medical1 trial
• Daiichi Sankyo1 trial
• Hoffmann-La Roche1 trial
• and 2 more

Running trials

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Corvia Medical· Source

• Active, not recruiting

  ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

  NCT03735667· Boston Scientific Corporation· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer1 recruiting

Closed trials

• Withdrawn

  TNBC Gut Microbiota During Neoadjuvant Treatment

  NCT06610097· Scripps Health· Source

• Completed

  Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

  NCT05966662· Shockwave Medical, Inc.· Source

• Completed

  An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

  NCT03662659· Phase 2· Bristol-Myers Squibb· Source